Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Author's Avatar
Nov 10, 2022

%3Cb%3ELucid+Diagnostics+Inc.%3C%2Fb%3E (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of %3Cb%3EPAVmed+Inc.%3C%2Fb%3E (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Lishan+Aklog%2C+M.D., the Lucid’s Chairman and Chief Executive Officer, will present an overview of the Company at the CG+MedTech%2C+Diagnostics+and+Digital+Health+%26amp%3B+Services+Forum taking place on November 17, 2022 from 11:00 am to 11:25 am EST at The+Westin+New+York+Grand+Central in the Grand Central A room.